• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

七个拉丁美洲城市的血脂异常:CARMELA 研究。

Dyslipidemia in seven Latin American cities: CARMELA study.

机构信息

InterAmerican Foundation for Clinical Research, 708 Third Avenue, Sixth Floor, New York, NY 10017, USA.

出版信息

Prev Med. 2010 Mar;50(3):106-11. doi: 10.1016/j.ypmed.2009.12.011. Epub 2009 Dec 23.

DOI:10.1016/j.ypmed.2009.12.011
PMID:20034514
Abstract

OBJECTIVE

The objective of this study was to describe the prevalence of dyslipidemia in the CARMELA study population.

METHODS

CARMELA was a cross-sectional study of cardiovascular risk conducted between September 2003 and August 2005 in adults (aged 25 to 64 years) living in Barquisimeto (n=1,824), Bogotá (n=1,511), Buenos Aires (n=1,412), Lima (n=1,628), Mexico City (n=1,677), Quito (n=1,620), and Santiago (n=1,605). Dyslipidemia was defined as the presence of one or more of the following conditions: triglycerides>/=200 mg/dL, or total cholesterol (TC)>/=240 mg/dL, or HDL cholesterol<40 mg/dL, or LDL cholesterol=not optimal, or currently taking antilipemic agents.

RESULTS

Prevalence rates of dyslipidemia in men and women were: 75.5% (CI: 71.9-79.1) and 48.7% (CI: 45.4-51.9) in Barquisimeto; 70% (CI: 66.2-73.8) and 47.7% (CI: 43.9-51.5) in Bogotá; 50.4% (CI: 46.8-54.0) and 24.1% (CI: 21.0-27.2) in Buenos Aires; 73.1% (CI: 69.3-76.8) and 62.8% (CI: 59.2-66.5) in Lima; 62.5% (CI: 58.5-66.5) and 37.5% (CI: 33.5-41.6) in Mexico City; 52.2% (CI: 47.9-56.5) and 38.1% (CI: 34.5-41.7) in Quito; and, 50.8% (CI: 47.1-54.4) and 32.8% (CI: 29.3-36.3) in Santiago.

CONCLUSIONS

Dyslipidemia was disturbingly prevalent and varied across cities. The most frequent dyslipidemia was low HDL-C followed by high triglycerides. The high TC/HDL-C ratios and non-HDL-C levels suggest a high risk of cardiovascular disease.

摘要

目的

本研究旨在描述 CARMELA 研究人群中的血脂异常患病率。

方法

CARMELA 是一项心血管风险的横断面研究,于 2003 年 9 月至 2005 年 8 月在居住在巴基西梅托(n=1824)、波哥大(n=1511)、布宜诺斯艾利斯(n=1412)、利马(n=1628)、墨西哥城(n=1677)、基多(n=1620)和圣地亚哥(n=1605)的成年人中进行。血脂异常定义为存在以下一种或多种情况:甘油三酯>/=200mg/dL,或总胆固醇(TC)>/=240mg/dL,或高密度脂蛋白胆固醇(HDL-C)<40mg/dL,或低密度脂蛋白胆固醇=不理想,或正在服用降脂药物。

结果

男性和女性血脂异常的患病率分别为:巴基西梅托 75.5%(CI:71.9-79.1)和 48.7%(CI:45.4-51.9);波哥大 70%(CI:66.2-73.8)和 47.7%(CI:43.9-51.5);布宜诺斯艾利斯 50.4%(CI:46.8-54.0)和 24.1%(CI:21.0-27.2);利马 73.1%(CI:69.3-76.8)和 62.8%(CI:59.2-66.5);墨西哥城 62.5%(CI:58.5-66.5)和 37.5%(CI:33.5-41.6);基多 52.2%(CI:47.9-56.5)和 38.1%(CI:34.5-41.7);圣地亚哥 50.8%(CI:47.1-54.4)和 32.8%(CI:29.3-36.3)。

结论

血脂异常的患病率令人担忧,且在不同城市之间存在差异。最常见的血脂异常是低 HDL-C,其次是高甘油三酯。高 TC/HDL-C 比值和非 HDL-C 水平提示心血管疾病风险较高。

相似文献

1
Dyslipidemia in seven Latin American cities: CARMELA study.七个拉丁美洲城市的血脂异常:CARMELA 研究。
Prev Med. 2010 Mar;50(3):106-11. doi: 10.1016/j.ypmed.2009.12.011. Epub 2009 Dec 23.
2
Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study.七个拉丁美洲城市的高血压:拉丁美洲心血管风险因素多重评估研究(CARMELA)。
J Hypertens. 2010 Jan;28(1):24-34. doi: 10.1097/HJH.0b013e328332c353.
3
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常:一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
4
Prevalence of dyslipidemia in the Iraqi adult population.伊拉克成年人群中血脂异常的患病率。
Saudi Med J. 2007 Dec;28(12):1868-74.
5
Rural-urban difference in lipid levels and prevalence of dyslipidemia: a population-based study in Khon Kaen province, Thailand.泰国孔敬府血脂水平及血脂异常患病率的城乡差异:一项基于人群的研究
J Med Assoc Thai. 2006 Nov;89(11):1835-44.
6
Lipid and lipoprotein profiles and prevalence of dyslipidemia in Mexican adolescents.墨西哥青少年的血脂和脂蛋白谱以及血脂异常患病率。
Metabolism. 2007 Dec;56(12):1666-72. doi: 10.1016/j.metabol.2007.07.009.
7
Tobacco smoking in seven Latin American cities: the CARMELA study.七个拉丁美洲城市的烟草使用情况:CARMELA 研究。
Tob Control. 2010 Dec;19(6):457-62. doi: 10.1136/tc.2009.031666. Epub 2010 Aug 13.
8
CARMELA: assessment of cardiovascular risk in seven Latin American cities.卡梅拉:拉丁美洲七个城市的心血管风险评估。
Am J Med. 2008 Jan;121(1):58-65. doi: 10.1016/j.amjmed.2007.08.038.
9
Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.美国有和没有心血管合并症的成年人血脂异常的患病率、程度及推荐的血脂水平:2003 - 2004年国家健康和营养检查调查
Am Heart J. 2008 Jul;156(1):112-9. doi: 10.1016/j.ahj.2008.03.005. Epub 2008 May 15.
10
Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study.拉丁美洲代谢综合征的流行情况及其与亚临床颈动脉粥样硬化的关系:CARMELA 横断面研究。
Cardiovasc Diabetol. 2009 Sep 26;8:52. doi: 10.1186/1475-2840-8-52.

引用本文的文献

1
Rural-urban differences in lipid abnormalities among middle-aged and older Indians.印度中老年人脂质异常的城乡差异。
BMC Public Health. 2025 Aug 22;25(1):2895. doi: 10.1186/s12889-025-22625-3.
2
Association of , , , and Gene Variants with Dyslipidemia and Cardiovascular Risk in a Population from Cauca Department, Colombia.哥伦比亚考卡省某人群中、、、和基因变异与血脂异常及心血管风险的关联
Genes (Basel). 2025 Apr 30;16(5):545. doi: 10.3390/genes16050545.
3
Data for population-based health analytics: the Cohorts Consortium of Latin America and the Caribbean.
基于人群的健康分析数据:拉丁美洲和加勒比地区队列联盟
Rev Panam Salud Publica. 2024 Dec 16;48:e59. doi: 10.26633/RPSP.2024.59. eCollection 2024.
4
Real-world data lipid profiles in one million colombian adults: The LiPAC million person study.一百万哥伦比亚成年人的真实世界数据血脂谱:LiPAC 百万人研究。
Atheroscler Plus. 2024 Nov 16;58:51-58. doi: 10.1016/j.athplu.2024.11.001. eCollection 2024 Dec.
5
Effectiveness of Chinese herbal medicine compared with angiotensin II receptor blockers in patients with diabetic kidney disease: A hospital-based matched cohort study.糖尿病肾病患者中中药与血管紧张素II受体阻滞剂疗效比较:一项基于医院的匹配队列研究。
J Tradit Complement Med. 2023 Nov 8;14(2):215-222. doi: 10.1016/j.jtcme.2023.11.002. eCollection 2024 Mar.
6
Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries.低收入和中等收入国家中高脂血症药物可及性的障碍。
PLOS Glob Public Health. 2024 Feb 12;4(2):e0002905. doi: 10.1371/journal.pgph.0002905. eCollection 2024.
7
Frequencies of variants in genes associated with dyslipidemias identified in Costa Rican genomes.在哥斯达黎加基因组中鉴定出的与血脂异常相关基因的变异频率。
Front Genet. 2023 Mar 30;14:1114774. doi: 10.3389/fgene.2023.1114774. eCollection 2023.
8
Trends and geographical variation in mortality from coronary disease in Peru.秘鲁冠心病死亡率的趋势和地域差异。
PLoS One. 2022 Sep 6;17(9):e0273949. doi: 10.1371/journal.pone.0273949. eCollection 2022.
9
Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function variants in non-Europeans.载脂蛋白C-III浓度的种族差异与心血管疾病风险:无证据表明非欧洲人中罕见/功能缺失变异具有心脏保护作用。
Am Heart J Plus. 2022 Jan;13. doi: 10.1016/j.ahjo.2022.100128. Epub 2022 Mar 31.
10
Management of hypertension and dyslipidemia in Mexico: Evidence, gaps, and approach.墨西哥高血压和血脂异常的管理:证据、差距与方法。
Arch Cardiol Mex. 2023 Feb 2;93(1):077-087. doi: 10.24875/ACM.21000330.